# Fate Therapeutics Inc. (FATE)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $234M  
**Price:** $1.97 (+5.35%)

> Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies using induced pluripotent stem cell (iPSC) technology to treat cancer and autoimmune diseases. The company's pipeline includes FT819, an off-the-shelf CAR T-cell candidate for systemic lupus erythematosus and other autoimmune conditions, which has demonstrated rapid B-cell depletion and durable clinical responses in Phase 1 studies with reduced or eliminated conditioning chemotherapy requirements. Additional programs include FT825 and FT836 for various solid tumors and hematologic cancers, and FT522 for B-cell lymphoma. Fate Therapeutics' approach focuses on multiplexed-engineered cell products designed to overcome manufacturing and development limitations inherent to traditional cell therapies. The company emphasizes the potential for same-day discharge and outpatient administration of its therapies, aiming to make cell therapy delivery more routine and accessible while addressing significant unmet medical needs in oncology and immunology.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $7M | — | -$148M | -$136M | — |
| 2024 | $14M | — | -$210M | -$186M | — |
| 2023 | $64M | — | -$191M | -$161M | — |
| 2022 | $96M | — | -$308M | -$282M | — |
| 2021 | $56M | — | -$217M | -$212M | — |
| 2020 | $31M | — | -$128M | -$173M | — |
| 2019 | $11M | — | -$101M | -$98M | — |
| 2018 | $5M | — | -$67M | -$67M | — |
| 2017 | $4M | — | -$42M | -$43M | — |
| 2016 | $4M | — | -$32M | -$33M | — |
| 2015 | $2M | — | -$28M | -$30M | — |
| 2013 | $971,000 | — | -$18M | -$21M | — |
| 2012 | $3M | — | -$14M | -$14M | — |
| 2011 | $1M | — | -$13M | -$13M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $319M | $112M | $207M | $47M | — |
| 2024 | $441M | $122M | $319M | $36M | — |
| 2023 | $506M | $138M | $368M | $42M | — |
| 2022 | $706M | $222M | $484M | $61M | — |
| 2021 | $921M | $243M | $679M | $134M | — |
| 2020 | $622M | $238M | $384M | $167M | — |
| 2019 | $302M | $58M | $245M | $100M | — |
| 2018 | $213M | $53M | $160M | $191M | $18M |
| 2017 | $105M | $28M | $77M | $89M | $19M |
| 2016 | $95M | $22M | $73M | $89M | $13M |
| 2015 | $68M | $30M | $38M | $65M | $22M |
| 2013 | $56M | $5M | $51M | $54M | $2M |
| 2012 | $11M | $64M | -$53M | $9M | $4M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$106M | $6M | -$112M |
| 2024 | -$123M | $730,000 | -$124M |
| 2023 | -$132M | $6M | -$138M |
| 2022 | -$248M | $36M | -$284M |
| 2021 | -$163M | $51M | -$214M |
| 2020 | -$39M | $5M | -$44M |
| 2019 | -$83M | $7M | -$91M |
| 2018 | -$39M | $2M | -$41M |
| 2017 | -$37M | $2M | -$39M |
| 2016 | -$30M | $457,000 | -$30M |

Source: [CompaniesByCap](https://companiesbycap.com/company/FATE)